News

The companies said that rapid recovery was seen in patients on ventilators and extracorporeal membrane oxygenation (ECMO) and having severe medical comorbidities following three days of treatment with

HEPCLUDEX has been approved as the first treatment option for adult patients with chronic hepatitis delta virus infection and compensated liver disease in Europe. The drug was originally

Sisunatovir is an orally administered fusion inhibitor designed to inhibit RSV replication by suppressing RSV F-mediated fusion of RSV with the host cell. RSV is a respiratory pathogen

Calidi has partnered with PSC for over two years—most recently contributing the stem cell lines used to manufacture treatment for the upcoming first trial, “CoronaStem 1,” which will

The hAd5 vaccine, which contains the spike (S) and also the nucleocapsid (N) SARS-CoV-2 proteins (hAd5 S + N), delivered strong T cell and humoral immune responses against

The study will include up to 2,400 participants and assess the ability of LY-CoV555 to prevent infection of long-term care residents and facility staff who have been exposed

The studies indicated that the Depakine has induced disabilities in about 15,000 to 30,000 children whose mothers took the drug valproate during pregnancy. The drug, which has been

The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established

The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review.  The review was also conducted under Project Orbis, an initiative of the FDA Oncology Center